Shamama Nishat
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
18
Citations
98
Est. group size
~4
Recurring co-author estimate
Active years
15
Publishing since 2012
This researcher's publication record spans a broad mix of topics, including cardiovascular biology (adenosine and nitric oxide signaling, cardiac fibrosis), cancer immunotherapy (CAR-T cell therapy for blood cancers), and computational drug discovery (molecular docking and simulation studies of candidate compounds). The work combines laboratory experiments (e.g., in zebrafish and cell models), clinical trial reporting, and computer-based modeling approaches to studying disease mechanisms and potential treatments.
Publication output was minimal or absent in the mid-2010s but has grown noticeably since 2021, with the most active years being 2023 and 2025-2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22
Research Square · 2026
- Immunogenetic modulation of endothelial inflammation by the LIPG −384A/C promoter variant influences COVID-19 severity
Frontiers in Immunology · 2026
- In-situ gel bases ocular delivery system of Ganciclovir, in-vivo and in-vitro investigation
BMC Pharmacology and Toxicology · 2025
- Inhibitory Activity of Chalcones as MAO‐B Inhibitors: An Insight from Molecular Docking, ADME Analysis, MD Simulation, and MM‐PBSA Calculations
ChemistrySelect · 2025
- Targeting the DNA damage response through TBL1X in mantle cell lymphoma
Blood Advances · 2025
- Electronic Structure and Topology‐Based Insights into Andrographolides as Potential CDK2 Inhibitors: Comprehensive DFT and Molecular Dynamics Investigation
Advanced Theory and Simulations · 2025
- Initial Results of a First-in-Human, Phase I Study Point-of-Care Manufacturing of Trispecific CAR-T Cells Targeting CD19/20/22 in B-Cell Malignancies
Blood · 2024
- A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models
Experimental Hematology and Oncology · 2023
- In Silico and In Vitro Methods in the Characterization of Beta-Carotene as Pharmaceutical Material via Acetylcholine Esterase Inhibitory Actions
Molecules · 2023
- Preventive Action of Beta-Carotene against the Indoxyl Sulfate-Induced Renal Dysfunction in Male Adult Zebrafish via Regulations of Mitochondrial Inflammatory and β-Carotene Oxygenase-2 Actions
Biomedicines · 2023
- Ectonucleoside triphosphate diphosphohydrolase-1 (CD39) impacts TGF-β1 responses: insights into cardiac fibrosis and function following myocardial infarction
American Journal of Physiology-Heart and Circulatory Physiology · 2022
- The chicken, the egg, and the elephant: eNOS and NRG1 in fibrosis
American Journal of Physiology-Heart and Circulatory Physiology · 2021
- Abstract MP259: The Role Of Sertad4 In Pathological Cardiac Remodeling
Circulation Research · 2021
- ROLE OF NIGELLA SATIVA IN RENOPROTECTION
International journal of scientific research · 2019
- Adenosine A<sub>3</sub> Receptor: A promising therapeutic target in cardiovascular disease
Current Cardiology Reviews · 2016
- American Journal of Physiology-Heart and Circulatory Physiology×2
- Experimental Hematology and Oncology×1
- BMC Pharmacology and Toxicology×1
- Current Cardiology Reviews×1
- Molecules×1
- Kyle Gordon
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Marina Capece
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Fedias L. Christofi
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Mikhail M. Dikov
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Rachel A. Brown
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile